Actively Recruiting
Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes
Led by The First Affiliated Hospital with Nanjing Medical University · Updated on 2026-04-30
60
Participants Needed
1
Research Sites
126 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to investigate whether a class of diabetes medications called GLP-1 receptor agonists (GLP-1RA), specifically semaglutide or polyethylene glycol loxenatide, can improve heart-related nerve damage in people with type 2 diabetes. This heart-related nerve damage is known as diabetic cardiac autonomic neuropathy (DCAN), which can cause problems such as fast resting heart rate, low blood pressure upon standing, and in severe cases, heart attack or sudden death. In this study, 60 adults with type 2 diabetes (ages 18-80) will be randomly divided into two groups. One group will receive standard diabetes care only, while the other group will receive standard care plus a once-weekly injection of either semaglutide or polyethylene glycol loxenatide for 6 months. Participants will undergo tests before and after the treatment period, including blood tests and non-invasive heart function tests (24-hour heart rate variability monitoring and cardiac autonomic reflex tests). The main goal is to see whether GLP-1RA treatment improves heart rate variability, a key sign of heart nerve function. The study also looks at changes in body weight, blood sugar control, and insulin resistance. This research may help determine whether GLP-1RA medications can protect against or improve diabetic heart nerve damage, beyond their known benefits for blood sugar control.
CONDITIONS
Official Title
Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 18-70 years
- Diagnosed with type 2 diabetes mellitus according to diagnostic guidelines
- Signed the informed consent form
- Overweight or obese with a body mass index (BMI) of 24 kg/m² or higher
You will not qualify if you...
- Younger than 18 years
- Pregnant or breastfeeding women
- Acute or chronic pancreatitis
- Recent acute diabetic complications such as diabetic ketoacidosis or hyperosmolar hyperglycemic state
- Arrhythmia or use of medications affecting heart rate (beta-blockers, non-dihydropyridine calcium channel blockers, antiarrhythmic drugs)
- Thyroid disease
- Severe organ dysfunction including heart, liver, or kidney failure
- Declined to provide informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
the First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China, 210029
Actively Recruiting
Research Team
J
jianbo Li
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here